Christina S. Baik

Efficacy of Larotrectinib in <i>TRK</i> Fusion–Positive Cancers in Adults and Children

Alexander Drilon, Theodore W. Laetsch, Shivaani Kummar et al. · New England Journal of Medicine · 2018 · 2.6K citations · Full text

Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial

David Planchard, Benjamin Besse, Harry J.M. Groen et al. · The Lancet Oncology · 2016 · 867 citations · Full text

Multicentre Phase 2, Medicine, Metronomic Therapy +6

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study

Justin F. Gainor, Giuseppe Curigliano, Dong‐Wan Kim et al. · The Lancet Oncology · 2021 · 428 citations · Full text

Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study

Vivek Subbiah, Mimi I. Hu, Lori J. Wirth et al. · The Lancet Diabetes & Endocrinology · 2021 · 330 citations

Medicine, Thyroid Disease, Pathology +8

Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis

David Planchard, Benjamin Besse, Harry J.M. Groen et al. · Journal of Thoracic Oncology · 2021 · 253 citations · Full text